Showing results (1-10 of 596) with videos related to
Sort By:
Pageof 60
Expert Opinion on Therapeutic Patents|August 7, 2010
Overview perspective of bacterial resistanceGuilherme H Furtado, David P NicolauAntimicrobial Agents and Chemotherapy|April 27, 2011
In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing EnterobacteriaceaeDora E Wiskirchen, Jared L Crandon, Guilherme H Furtado, et al.The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|January 11, 2012
Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in ColombiaMaria Virginia Villegas, David Felipe Briceno, Sory Jamil Ruiz, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 17, 2018
Immediate and later impacts of antimicrobial consumption on carbapenem-resistant Acinetobacter spp., Pseudomonas aeruginosa, and Klebsiella spp. in a teaching hospital in Brazil: a 10-year trend studyMarilia P Federico, Guilherme H FurtadoExpert Opinion on Pharmacotherapy|March 5, 2004
Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycinDavid P NicolauExpert Opinion on Pharmacotherapy|December 14, 2007
Carbapenems: a potent class of antibioticsDavid P NicolauCurrent Opinion in Infectious Diseases|January 5, 2011
Current challenges in the management of the infected patientDavid P NicolauJournal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 24, 2003
Optimizing outcomes with antimicrobial therapy through pharmacodynamic profilingDavid P NicolauCritical Care (London, England)|June 17, 2008
Pharmacodynamic optimization of beta-lactams in the patient care settingDavid P NicolauExpert Opinion on Investigational Drugs|July 7, 2015
Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infectionsDavid P NicolauPageof 60